Vitrolife AB logo

VITR - Vitrolife AB Share Price

SEK219.4 1.2  0.6%

Last Trade - 2:22pm

Sector
Healthcare
Size
Mid Cap
Market Cap £2.08bn
Enterprise Value £2.02bn
Revenue £116.9m
Position in Universe 189th / 1782
Bullish
Bearish
Unlock VITR Revenue
Momentum
Relative Strength (%)
1m +2.80%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.88%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
510.5 722.4 856.1 1,046 1,151 1,480 1,258 1,497 +23.7%
+94.9 +53.4 +4.3 +38.3 +22.3 +18.8 -31.0 +46.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Vitrolife AB revenues decreased 22% to SEK543M. Net income applicable to common stockholders decreased 49% to SEK91.5M. Revenues reflect EMEA segment decrease of 74% to SEK72.9M, Asia segment decrease of 68% to SEK59.1M. Net income also reflects Other operating revenues decrease of 51% to SEK5.7M (income), Research and development costs increase of 6% to SEK47.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for VITR
Graphical History

Revenue

VITR Revenue Unlock VITR Revenue

Net Income

VITR Net Income Unlock VITR Revenue

Normalised EPS

VITR Normalised EPS Unlock VITR Revenue

PE Ratio Range

VITR PE Ratio Range Unlock VITR Revenue

Dividend Yield Range

VITR Dividend Yield Range Unlock VITR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VITR EPS Forecasts Unlock VITR Revenue
Profile Summary

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since June 26, 2001
No. of Shareholders: 10,064
No. of Employees: 418
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 108,550,575
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VITR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VITR
Upcoming Events for VITR
Friday 6th November, 2020
Q3 2020 Vitrolife AB Earnings Release
Friday 6th November, 2020
Q3 2020 Vitrolife AB Earnings Call
Frequently Asked Questions for Vitrolife AB
What is the Vitrolife AB share price?

As of 2:22pm, shares in Vitrolife AB are trading at SEK219.4, giving the company a market capitalisation of £2.08bn. This share price information is delayed by 15 minutes.

How has the Vitrolife AB share price performed this year?

Shares in Vitrolife AB are currently trading at SEK219.4 and the price has moved by 22.93% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vitrolife AB price has moved by 28.38% over the past year.

What are the analyst and broker recommendations for Vitrolife AB?

Of the analysts with advisory recommendations for Vitrolife AB, there are there are currently 0 "buy" , 0 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Vitrolife AB is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Vitrolife AB next release its financial results?

Vitrolife AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Vitrolife AB dividend yield?

Vitrolife AB does not currently pay a dividend.

Does Vitrolife AB pay a dividend?

Vitrolife AB does not currently pay a dividend.

When does Vitrolife AB next pay dividends?

Vitrolife AB does not currently pay a dividend.

How do I buy Vitrolife AB shares?

To buy shares in Vitrolife AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vitrolife AB?

Shares in Vitrolife AB are currently trading at SEK219.4, giving the company a market capitalisation of £2.08bn.

Where are Vitrolife AB shares listed? Where are Vitrolife AB shares listed?

Here are the trading details for Vitrolife AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: VITR
What kind of share is Vitrolife AB?

Based on an overall assessment of its quality, value and momentum, Vitrolife AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vitrolife AB share price forecast 2020?

Shares in Vitrolife AB are currently priced at SEK219.4. At that level they are trading at 16.48% premium to the analyst consensus target price of 0.00.

Analysts covering Vitrolife AB currently have a consensus Earnings Per Share (EPS) forecast of 2.433 for the next financial year.

How can I tell whether the Vitrolife AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitrolife AB. Over the past six months, the relative strength of its shares against the market has been 33.5%. At the current price of SEK219.4, shares in Vitrolife AB are trading at 18.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vitrolife AB PE Ratio?

The Vitrolife AB PE ratio based on its reported earnings over the past 12 months is 80.48. The shares are currently trading at SEK219.4.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Vitrolife AB?

Vitrolife AB's management team is headed by:

Barbro Friden - IND
Mikael Engblom - CFO
Thomas Axelsson - CEO
Maria Forss - VPR
Pia Marions - IND
Fredrik Mattsson - SVP
Jon Sigurdsson - CHM
Rickard Ericsson - CMO
Steffen Nielsen - COO
Lars Holmqvist - IND
Henrik Blomquist - IND
Mark Larman - CSO
Claus Bisgaard - CTO
Who are the major shareholders of Vitrolife AB?

Here are the top five shareholders of Vitrolife AB based on the size of their shareholding:

Oticon Fonden Corporation
Percentage owned: 25.9% (28.1m shares)
Bure Equity AB Private Equity
Percentage owned: 18.95% (20.6m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 4.61% (5.00m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 4.61% (5.00m shares)
Morgan Stanley Investment Management (Singapore) Investment Advisor/Hedge Fund
Percentage owned: 4.28% (4.64m shares)
Similar to VITR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.